Bringing together the brightest minds in cancer research, our experts break new ground in the way we prevent, screen, treat and care for patients with cancer. We have significant capability in many areas of cancer research. The CRN currently hosts 10 Special Interest Groups.
The new AI in Cancer Care Special Interest Group (AICC SIG) centres on informing and promoting applied cancer research using AI systems in clinical care, clinical decision-making, and population health practice in cancer.
It brings together researchers with interests and expertise in this rapidly evolving, multidisciplinary field including machine learning, natural language processing, statistical and cyber systems that replicate human decision-making ability and experts in the application of AI in cancer research and practice. The SIG encompasses all aspects of AI application including clinical, methodological and psycho-social research.
Involvement in the AICC SIG provides you with opportunities to connect with other researchers and AI experts in the technical and the applied settings, and to share and expand your knowledge in the latest AI research and developments as it relates to cancer practice.
The Brain Tumour Research Special Interest Group (BTRSIG) brings together experts and clinicians that are interested in research that relates to brain tumour prevention, early detection, treatment, health services, health economics or psycho-social impact.
Involvement in the BTRSIG is a great opportunity to discuss new and exciting research in this area, brush up on and expand your knowledge of relevant techniques, discuss possibilities for collaborative research, share your knowledge, and interact with researchers who share your interests.
The Breast Cancer Special Interest Group (BCSIG) brings together a multidisciplinary team of well-established researchers with backgrounds in physiotherapy, oncology, diagnostic testing and imaging, surgery, biology, clinical exercise physiology, evidence synthesis, public health and psychology.
The group focuses on identifying, preventing and modifying risk of breast cancer and its sequelae, including the short and long-term sequelae of breast cancer treatments, to improve prognosis and overall quality of life. It also explores methods of optimising early detection.
Bowel (colorectal) cancer is Australia’s third most common malignancy and second deadliest cancer, claiming approximately 100 lives each week.
Key issues the Bowel Cancer SIG addresses include (1) Prevention and screening (2) Curative pathways (3) Metastatic disease and palliative pathways for CRC patients (4) Public health and guideline development
By harnessing the strengths of researchers at The University of Sydney and its clinical partners, we can better address this health burden through research. The Bowel Cancer SIG will enhance research opportunities through collaboration and sharing of expertise and underpin more competitive large-scale grant applications.
The Comparative Oncology Special Interest Group (CO-SIG) links together human and animal cancer researchers to exploit animal cancer models as a means of generating new knowledge of understanding in basic cancer mechanisms as well as their treatment.
Involvement in CO-SIG is a great opportunity to be part of building an Australia-Asia recognised research facility for the integration of naturally occurring cancer models into the development of novel cancer research and treatments for humans and animals.
The Clinically Informed Drug Discovery Special Interest Group (CIDDSIG) aims to bridge the current gap between clinical experiences and drug development. It brings together researchers that are specializing in the development of new cancer therapies and the discovery of new anticancer drugs to enhance cancer research and treatment innovation.
Involvement in the CIDDSIG provides you with opportunities to foster connections between these two research groups and to utilize facilities that significantly contribute to collaborative efforts and advancements in clinically informed drug discovery.
The Diagnosis to Rehabilitation, Survivorship and Palliative care in Cancer Research Translation Special Interest Group (DIRECTSIG) has been established to facilitate and support effective, integrative, multi-disciplinary, multi-faculty, multi-institutional translational research across the entirety of the individual’s cancer journey.
The DIRECT group brings together researchers who are active in researching different aspects of the cancer patient’s journey that commences with its diagnosis, progressing through treatment and rehabilitation to return to the community, or for some, to palliative care. By gathering these researchers under one banner, ideas and support can be generated and shared, which will enable synergies to be identified and developed.
The Melanoma & Skin Cancer Special Interest Group (MELSIG) brings together experts that are interested in research that relates to melanoma and other skin cancers, including prevention, early detection, treatment, health services, health economics or psycho-social impact.
Involvement in the MELSIG will let you discuss new and exciting research in this area, brush up on and expand your knowledge of relevant techniques, discuss possibilities for collaborative research, share your knowledge, and interact with researchers who share your interests.
Pancreatic cancer is the most aggressive and difficult to treat cancer affecting Australians, and treatment options for most patients are limited to chemotherapy with poor efficacy and high rates of resistance.
Improving early detection of pancreatic cancer and developing more effective therapeutic approaches are key issues in Pancreatic Cancer treatment. We are well positioned to address both these areas through our network of expert researchers, advanced infrastructure and relationships with leading pancreatic cancer treatment centers.
The Pancreatic Cancer SIG will bring together interested researchers and enhance opportunities for collaboration and sharing of expertise, resources and new technologies. This will enable the development of high-scale grant applications and markedly enhance our research impact, with high potential for clinical translation.
The Patient Reported Outcomes Special Interest Group (PRO-SIG) is involved in conducting quality PRO research to achieve the best possible quality of life for people affected by cancer, their families, healthcare providers and funders. It is a multidisciplinary endeavour, requiring insights and methods from medicine, psychology and statistics.
The Cancer Research Network includes some world leaders in various aspects of health-related quality of life (HRQOL) and PRO assessment. PRO-SIG enables the expertise of those few individuals to flow and grow into a critical mass, to ensure that members of our network conduct world-class PRO research.
The Prostate Cancer Special Interest Group (PCaSIG) brings together prostate cancer researchers from across the University of Sydney to enhance current research activities and create strategic partnerships.
Involvement in PCaSIG is a great opportunity to address acute research problems in this area, discuss possibilities for collaborative research, develop long-term strategic research partnerships leading to major research funding outcomes, and interact with researchers who share your interests.
The Cancer Research Network would like to hear from members who are interested in starting a Special Interest Group (SIG) in cancer research.
The purpose of SIGs is to facilitate the transfer of knowledge and promote collaboration between members of the CRN who share common research interests.